Comvita Earnings Call Highlights Turnaround And Risks

Comvita ((CVNZF)) has held its Q2 earnings call. Read on for the main highlights of the call.

Comvita’s latest earnings call struck a decidedly upbeat tone, with management emphasizing a return to profitability, sharply better cash metrics, and firm progress on recapitalization. While persisting challenges in China, ANZ and gross margins tempered the message, executives argued that operational gains and balance sheet repair now firmly outweigh the remaining risks.

Return to Profitability and Cash Flow

Comvita confirmed it met its H1 objectives by moving back into the black and generating positive operating cash flow, marking a clear break from prior stress. Management also reaffirmed its FY’26 normalized EBIT target of $14.3m, or $13.5m on a pre‑IFRS 16 basis, underlining confidence in the earnings trajectory.

Inventory Normalization Unlocks Working Capital

Inventory has been cut from $145.8m in December 2023 to $68.3m by 31 December 2025, a reduction of about 53.2%. Executives highlighted that this normalization was largely achieved without heavy discounting, materially freeing up working capital and easing balance sheet pressure.

Accelerated Deleveraging Reduces Net Debt

Net debt fell to $48.7m at H1 FY’26, down from $62.4m at the end of FY’25 and from $81.6m a year ago, representing a roughly one‑third reduction. The faster‑than‑planned deleveraging strengthens Comvita’s financial resilience and gives the company more room to navigate market volatility.

Cash Conversion Cycle Halved

The cash conversion cycle improved dramatically from 484 days to 239 days, an improvement of 245 days or about 50.6%. Management attributed this primarily to selling through excess inventory, turning stock into cash much more quickly than in previous periods.

U.S. Club Retail Drives Growth

U.S. club retail emerged as a standout, delivering strong volume and sales growth along with better profitability. This channel also helped absorb overheads, and its performance, combined with other diversified channels, helped offset weaker regions and lifted overall net contribution.

Innovation and New Product Momentum

Comvita is leaning into innovation with new Manuka flavors such as Yuzu and Ginger and an expanded lozenge range. The company expects sales for this total range, including the fresh launches, to increase by more than 60% in the current financial year, signaling strong consumer traction.

Cost Savings and Operational Efficiency

Disciplined cost management and FY’25 cost‑out programs delivered procurement, formulation and freight efficiencies, alongside streamlined leadership and headcount. Increased manufacturing volumes in New Zealand have further improved plant efficiency, supporting margins and earnings quality.

Leadership and Strategy Upgrade

Comvita has filled key executive positions including CFO, COO and a Chief People & Culture Officer, bolstering global leadership depth. Management argued this refreshed team is critical for maintaining execution discipline and sharpening strategic focus as the turnaround progresses.

Recapitalization Options Take Shape

The recapitalization process is advancing, with credible interest from both existing and new investors, including an offshore strategic party. That investor is willing to underwrite an equity raise at $0.80 per share at a level above the minimum $25m, subject to approvals, suggesting market confidence in the recovery.

Category Tailwinds and Market Opportunities

The Manuka category reached a new peak value in 2025, with North America highlighted as the fastest‑growing region. Management sees substantial long‑term upside and is pursuing targeted diversification across channels and geographies to capture this structural growth.

Persistent Weakness in China

Greater China remains a weak spot, with subdued consumer confidence, sluggish demand and commoditization pressure, especially in lower UMF grades. Despite holding the number‑one online brand position and stabilizing net contribution, overall sales are still down in the region.

ANZ Underperformance Drags Results

Most markets posted gains in sales and net contribution, but ANZ continued to underperform and remains a material drag. This regional weakness stands out as a key operational headwind that Comvita must address to sustain group‑wide momentum.

Historic Gross Margin Compression

Gross margin in FY’25 fell to 43% from 54% a year earlier, an 11‑point decline that still weighs on investor confidence. Management maintained a medium‑term gross margin goal of about 51%, but stressed that the pace of recovery depends on flawless execution and seasonal trading outcomes.

Pricing Pressure and Commoditization

Average price per kilo has fallen as surplus supply, rising competition and commoditization—especially in lower‑grade honey—put pressure on pricing. These trends challenge margins and reinforce the need for brand strength, premium positioning and product differentiation.

Seasonality and Yield Uncertainty

The latest Manuka honey season was described as mixed and not as settled as the company would like, even though yields should align with baseline assumptions. Management flagged that seasonal factors, including key Q3 trading windows and Lunar New Year, could materially sway H2 performance.

Funding and Recapitalization Risks

While recapitalization discussions are progressing, the process is not yet complete and the banking facility expires in April 2026. Potential dilution from any capital raise and the need for shareholder and other approvals remain overhangs until a final funding solution is locked in.

Limited Further Working Capital Upside

After the sharp inventory and cash cycle improvements, management cautioned that similar gains are unlikely in H2. With the easy wins largely captured, future cash‑generation will depend more on sustained profitability and margin improvement than on working capital release.

North America Net Contribution Mix Pressure

Net contribution grew in North America overall, but the net contribution percentage declined, as New Zealand manufacturing efficiency benefits were excluded from that metric. This hints at some mix or pricing pressure even in a growth market, and investors will watch for margin stabilization.

FX and ANZ Headwinds Weighed

Foreign exchange volatility and ongoing ANZ weakness were cited as notable headwinds, though currently offset by better performance elsewhere. The company uses hedging to manage FX risk, but currency swings remain a meaningful sensitivity for earnings.

One‑off Transaction Costs Drag Results

H1 FY’26 included $1.4m of transaction costs that temporarily depressed reported earnings. Management framed these as short‑term items linked to the recapitalization process, with limited impact on the underlying operational turnaround.

Guidance and Outlook

The board reiterated FY’26 normalized EBIT guidance of $14.3m and a medium‑term gross margin target near 51%, supported by big gains in inventory, debt and cash conversion. Management expects Manuka yields to match baseline assumptions, sees over 60% sales growth in the lozenge and Manuka range, and remains confident in securing recapitalization ahead of the April 2026 facility expiry, while acknowledging seasonal uncertainty in the near term.

Comvita’s call painted a picture of a business that has done the hard work to stabilize operations and repair its balance sheet, even as some markets and margins remain under pressure. Investors will now look for confirmation that the earnings recovery, product momentum and pending recapitalization can collectively translate into a more durable and profitable growth story.